The provided bar chart depicts total costs on medical research by 5 companies during from 2012 to 2018 and provides a forecast for 2030.
Overall, it is evident that the amount of money spent on inquiry by each company has risen. For instance, spendings of Flemin have doubled in 2018, compared to 2012. It can be noticed that Bioharm has experienced a major improvement in expenses. The least change has been made in Pharm, the rise was from approximately 8 billion dollars in 2012 to 13 billion dollars in 2018.
If we take a closer look at the estimation of expenditures in 2030, it can be noticed that the most significant rise will happen to the Novas company (about 56 billion dollars). However, a smoother increase will be experienced by Avicena or Pharm corporation. Steady rise in spendings of research can be explained by a stable position in the field and lack of need to conduct major analysis.
